Angiotensin III (human, mouse): Advanced Insights for Cardiovascular and Viral Pathogenesis Research

Introduction

The renin-angiotensin-aldosterone system (RAAS) orchestrates critical physiological processes, including blood pressure regulation, fluid balance, and neuroendocrine signaling. Within this complex network, Angiotensin III (human, mouse) (CAS: 13602-53-4), a biologically active hexapeptide with the sequence Arg-Val-Tyr-Ile-His-Pro-Phe, has emerged as a central player in both cardiovascular research and studies of viral pathogenesis. Recent advances reveal Angiotensin III as more than a simple metabolite of angiotensin II—it is a multifaceted renin-angiotensin-aldosterone system peptide with distinct receptor interactions, potent pressor and aldosterone-inducing activities, and emerging relevance in the context of infectious diseases such as COVID-19.

This article presents a comprehensive, integrative analysis of Angiotensin III, emphasizing advanced mechanistic insights, translational research applications, and novel intersections with viral pathogenesis. Unlike previous reviews that primarily focus on mechanistic or workflow aspects, we explore the dynamic interface of cardiovascular and viral research, providing a forward-looking perspective for investigators seeking to leverage this peptide in next-generation models.

Biochemical Profile and Synthesis

Peptide Sequence and Structure

Angiotensin III is a hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe), generated through the N-terminal cleavage of angiotensin II by angiotensinase activity in erythrocytes and tissues. With a molecular weight of 931.09 and a chemical formula of C₄₆H₆₆N₁₂O₉, this peptide exhibits excellent solubility in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), and DMSO (≥93.1 mg/mL), facilitating its use in diverse experimental systems. For optimal stability, it is recommended to store Angiotensin III desiccated at -20°C, avoiding long-term storage in solution.

Mechanism of Action of Angiotensin III (human, mouse)

Receptor Interactions and Signaling Pathways

Angiotensin III is a potent AT1 and AT2 receptor ligand, binding both subtypes but showing relative specificity for the AT2 receptor. This dual interaction is significant: activation of the AT1 receptor mediates classic pressor responses, vasoconstriction, and aldosterone secretion, whereas AT2 receptor activation is associated with vasodilation, anti-inflammatory, and anti-fibrotic effects. Notably, Angiotensin III retains full aldosterone secretion inducer capability, paralleling angiotensin II, but mediates approximately 40% of the latter's pressor activity (see Angiotensin III [human, mouse] product).

Role in the Renin-Angiotensin-Aldosterone System

Within the RAAS cascade, Angiotensin III arises from angiotensin II metabolism and continues to influence vascular tone, sodium retention, and neuroendocrine signaling. Its ability to mimic both pressor and dipsogenic responses in rodent brain models underscores its value as a cardiovascular research peptide and a neuroendocrine signaling peptide. Experimental studies confirm that exogenous Angiotensin III induces aldosterone secretion, suppresses renin release, and contributes to homeostatic feedback within the RAAS.

Angiotensin III in Cardiovascular and Hypertension Research

Pressor Activity and Aldosterone Induction

Angiotensin III's capacity as a pressor activity mediator is well characterized. It triggers vasoconstriction and elevates blood pressure in both in vitro and in vivo models, albeit with slightly reduced potency compared to angiotensin II. Importantly, it maintains full efficacy in stimulating aldosterone release from the adrenal cortex, which is pivotal for sodium retention and blood pressure regulation. This unique pharmacodynamic profile positions Angiotensin III as an indispensable tool for hypertension research and the development of cardiovascular disease models.

Distinct Applications Compared to Angiotensin II and IV

While Angiotensin II has been the traditional focus of RAAS studies, Angiotensin III's enhanced specificity for the AT2 receptor offers a pathway to dissect signaling mechanisms not accessible via angiotensin II alone. For example, researchers investigating the balance between pro-hypertensive (AT1-mediated) and protective (AT2-mediated) signaling can benefit from the selective use of Angiotensin III to illuminate AT2 receptor function in cardiovascular remodeling and inflammation.

Emerging Role in Viral Pathogenesis: Insights from SARS-CoV-2 Research

Angiotensin Peptides and Viral Entry Mechanisms

Recent findings highlight a paradigm shift in our understanding of RAAS peptides in the context of viral infections. Angiotensin peptides, including Angiotensin III, have been shown to modulate the binding of the SARS-CoV-2 spike protein to host cell receptors. In a seminal study by Oliveira et al. (2025, Int. J. Mol. Sci.), naturally occurring angiotensin peptides, especially those resulting from N-terminal cleavage such as Angiotensin III (2–8), significantly enhanced spike protein binding to the AXL receptor—a newly identified route for SARS-CoV-2 entry, particularly in cells with low ACE2 expression.

While much attention has been paid to the role of angiotensin II and its C-terminal derivatives, Oliveira et al. found that N-terminally truncated peptides like Angiotensin III and IV exhibited even greater capacity to enhance spike–AXL interactions compared to their full-length counterparts. This suggests a potential mechanistic link between RAAS dysregulation and increased vulnerability to viral infection, underscoring the need for further investigation of Angiotensin III in viral pathogenesis models.

Therapeutic Implications and Research Directions

The intersection of RAAS peptides and viral entry opens new avenues for therapeutic targeting. By elucidating the specific contributions of Angiotensin III to spike protein–receptor interactions, researchers may identify novel strategies to disrupt viral entry or mitigate COVID-19 pathogenesis. Moreover, understanding the structural determinants—such as the presence and modification of tyrosine residues in Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe)—could inform the design of competitive inhibitors or receptor decoys.

Comparative Analysis with Alternative Models and Peptides

Existing literature has explored the advanced mechanistic roles of Angiotensin III, emphasizing its importance in disease modeling and receptor signaling. For example, one review provides a deep dive into molecular mechanisms and disease relevance, while another article focuses on receptor signaling and pathophysiological implications in cardiovascular and viral disease.

Building upon these foundations, our analysis uniquely emphasizes the translational bridge between cardiovascular and viral research, specifically highlighting Angiotensin III's emerging role in modulating viral entry mechanisms. Whereas previous works primarily detail classic RAAS functions, we integrate recent discoveries on AXL-mediated SARS-CoV-2 infection, providing actionable insights for dual-purpose experimental models. This perspective is distinct from the workflow-oriented guidance found in applied workflows articles, which focus more on troubleshooting and technical aspects in cardiovascular and neuroendocrine models.

Advanced Applications in Experimental Design

Cardiovascular Disease Models

By leveraging the unique receptor selectivity and robust aldosterone-stimulating activity of Angiotensin III, researchers can develop sophisticated cardiovascular disease models that dissect the interplay between AT1 and AT2 receptor signaling. Its partial pressor activity enables nuanced modulation of vascular tone, while full aldosterone induction allows for precise studies of sodium balance and hypertensive pathophysiology.

Neuroendocrine Signaling and Brain Research

In neuroendocrine contexts, Angiotensin III is instrumental for mapping dipsogenic and pressor responses in rodent brain models. Its capacity to cross the blood-brain barrier and engage both central and peripheral RAAS components positions it as a valuable neuroendocrine signaling peptide for studies of thirst regulation, stress response, and central blood pressure control.

Viral Pathogenesis and Host–Pathogen Interactions

The discovery that Angiotensin III enhances SARS-CoV-2 spike protein binding to alternative host receptors such as AXL (Oliveira et al., 2025) opens the door to experimental models that integrate cardiovascular and infectious disease pathways. Investigators can now use Angiotensin III to probe the consequences of RAAS peptide fluctuations in viral susceptibility, disease severity, and therapeutic intervention.

Practical Considerations for Experimental Use

The Angiotensin III (human, mouse) A1043 reagent offers high purity, robust solubility, and reliable storage properties, making it suitable for a wide range of in vitro and in vivo assays. Its application spans receptor binding studies, pressor response assays, aldosterone measurement, and now, spike protein–receptor interaction models relevant to COVID-19 and other viral diseases.

Conclusion and Future Outlook

Angiotensin III (human, mouse) stands at the intersection of cardiovascular, neuroendocrine, and viral pathogenesis research. As a potent renin-angiotensin-aldosterone system peptide with unique receptor affinities and emerging roles in viral entry, it provides researchers with a versatile tool for advanced experimental design. The integration of recent findings—such as its modulation of SARS-CoV-2 spike–AXL binding—propels Angiotensin III beyond traditional cardiovascular research, positioning it as a key reagent for studying the interplay of host peptide systems and infectious disease mechanisms.

Future research should further elucidate the molecular determinants of Angiotensin III's receptor interactions, its downstream signaling consequences in health and disease, and its translational potential in both cardiovascular and antiviral therapeutics. By building upon, yet extending beyond, prior mechanistic and workflow-focused reviews, this article highlights the dynamic and evolving relevance of Angiotensin III in contemporary biomedical science.